RANKL acts an unfavorable prognostic biomarker and potential target in advanced KRAS-mutated lung adenocarcinoma.

Hong-Shuai LiCheng-Ming LiuYan Wang

Published in: Thoracic cancer (2023)

RANKL acts as an unfavorable prognostic biomarker for patients with advanced KRAS-mt LUAD. Inhibition of RANKL may be a feasible strategy for this subset of patients.

Keyphrases

end stage renal disease
wild type
chronic kidney disease
bone loss
newly diagnosed
ejection fraction
peritoneal dialysis
prognostic factors
risk assessment
toll like receptor